Reviews in cardiovascular medicine最新文献

{"title":"Disruption of the Fibroinflammatory Loop: A Therapeutic Strategy for Cardiac Fibrosis in Non-Ischemic Cardiomyopathy.","authors":"Hongyu Qiu, Inna P Gladysheva","doi":"10.31083/RCM48589","DOIUrl":"10.31083/RCM48589","url":null,"abstract":"<p><p>In non-ischemic cardiomyopathy, inflammation is closely associated with cardiac fibrosis, which significantly contributes to adverse outcomes and promotes heart failure (HF). Recent mechanistic studies have demonstrated that interactions between fibrotic and inflammatory pathways create a dynamic, self-perpetuating fibroinflammatory loop, thereby accelerating disease progression. New mono or combination therapies that target this cycle by blocking specific inflammatory signals, modulating the immune response, and altering extracellular matrix (ECM) stiffness may halt or even reverse fibrosis. This opinion article discusses critical recent discoveries, current obstacles, and future opportunities in developing inflammation-focused treatments for cardiac fibrosis in non-ischemic cardiomyopathies.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"48589"},"PeriodicalIF":1.3,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Effect of Low-Density Lipoprotein Cholesterol and Homocysteine on Major Adverse Cardiovascular Events in Coronary Heart Disease: A Retrospective Cohort Study.","authors":"Baozhen Zhu, Xingyu Luo, Peng Wu, Yuru Ma, Bo Wu, Ru Yan, Tianshui Ma, Jiawei Yang, Ziyi Wang, Guangzhi Cong, Shaobin Jia","doi":"10.31083/RCM46290","DOIUrl":"https://doi.org/10.31083/RCM46290","url":null,"abstract":"<p><strong>Background: </strong>Residual cardiovascular risk remains substantial despite aggressive low-density lipoprotein cholesterol (LDL-C) lowering in coronary heart disease (CHD). Consequently, this elevated risk has spurred the search for non-lipid targets, such as homocysteine (HCY). However, the combined effect of HCY with LDL-C and the overall potential for combined risk stratification remain unclear.</p><p><strong>Methods: </strong>This retrospective cohort study included patients with CHD confirmed by coronary angiography or computed tomography angiography at the General Hospital of Ningxia Medical University between January 2019 and December 2021. Participants were stratified by baseline LDL-C levels (<1.8 vs. ≥1.8 mmol/L) and HCY (<15 vs. ≥15 μmol/L). Major adverse cardiovascular events (MACEs) were employed as the primary endpoint, defined as a composite of all-cause death, stroke, non-fatal myocardial infarction, or unplanned revascularization.</p><p><strong>Results: </strong>A total of 744 MACEs were recorded during the 25-month follow-up. Elevated levels of LDL-C (adjusted hazard ratio (aHR) = 1.38, 95% confidence interval (CI): 1.09-1.73) and HCY (aHR = 1.47, 95% CI: 1.19-1.81) were independently associated with a higher risk of MACEs. The risk was synergistic when both factors were elevated, as patients in the high LDL-C and high HCY group had a significantly increased risk (aHR = 1.97, 95% CI: 1.34-2.90) compared to the reference group with low levels.</p><p><strong>Conclusion: </strong>LDL-C and HCY are independent predictors of MACEs in patients with CHD, and the combined use of these indices improves risk stratification. Thus, integrating these indices into clinical practice could improve personalized management strategies and outcomes in this high-risk population.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"46290"},"PeriodicalIF":1.3,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Mechanisms and Therapeutic Strategies in Heart Failure Due to Dystrophin Deficiency: A Comprehensive Review.","authors":"Wanqian Yu, Wang Wang, Fan Luo, Yuanbin Zhao, Qinghua Wu, Ping Li","doi":"10.31083/RCM46389","DOIUrl":"https://doi.org/10.31083/RCM46389","url":null,"abstract":"<p><p>Dystrophin deficiency is the core pathological feature of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Indeed, a deficiency in dystrophin results in the progressive degeneration of skeletal muscle and severely compromises the structure and function of cardiomyocytes, eventually leading to dilated cardiomyopathy and heart failure. Thus, this review provides an in-depth analysis of the molecular mechanisms underlying dystrophin-deficient cardiomyopathy, including membrane instability, calcium dysregulation, mitochondrial dysfunction, and fibrosis. The role of inflammatory responses in disease progression is also discussed. In addition, we evaluate current and emerging therapeutic strategies, including gene therapy, pharmacological interventions, and regenerative medicine approaches, and highlight recent preclinical and clinical trial data. Finally, we explore future directions in precision medicine, novel biomarkers for early detection, and combination treatment regimens, to provide a comprehensive resource for clinicians and researchers working in this challenging field.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"46389"},"PeriodicalIF":1.3,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Single-Dose Alirocumab on Efficacy and Safety After Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Single-Center Retrospective Real-World Study.","authors":"Pei Wang, Haixia Wang, Dongdong Yan, Zheng Zhang","doi":"10.31083/RCM47437","DOIUrl":"https://doi.org/10.31083/RCM47437","url":null,"abstract":"<p><strong>Background: </strong>Residual inflammation and persistent lipid abnormalities substantially increase the risk of adverse clinical outcomes in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PPCI). Although proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes, the efficacy, safety, and prognosis of these inhibitors when administered as a single dose after PPCI in real-world practice remain unclear.</p><p><strong>Method: </strong>A retrospective study of patients with acute ST-segment elevation myocardial infarction (STEMI) admitted between May 2023 and May 2024. Patients were assigned to an alirocumab group or a conventional treatment group based on whether a single dose of alirocumab was administered within 6 hours of PPCI. Baseline differences between groups were balanced using 1:1 propensity score matching (PSM). The occurrence of major adverse cardiovascular events (MACEs) at 12 months post-procedure was applied as the primary endpoint. Secondary endpoints included lipid profiles, inflammatory markers, cardiac function, quality-of-life changes, and safety outcomes.</p><p><strong>Results: </strong>A non-significant downward trend in the incidence of MACEs at 12 months post-PPCI was observed in the alirocumab group compared with the conventional treatment group (log-rank <i>p</i> = 0.242). A single dose of alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) at 1 month (<i>p</i> = 0.011) and attenuated inflammation markers at 24 hours postoperatively. At 12 months, the alirocumab group showed improved cardiac function with significantly reduced left ventricular end-systolic volume (LVESV, <i>p</i> = 0.009) and modest but statistically significant improvement in quality of life (<i>p</i> = 0.012), primarily driven by enhanced physical activity (<i>p</i> < 0.001), alongside reduced insecurity (<i>p</i> < 0.001). No increased incidence of adverse events was observed (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>This study demonstrated that a single dose of alirocumab in STEMI patients undergoing PPCI was associated with significant improvement in LDL-C levels, attenuation of early postoperative inflammation, and a favorable trend toward improved cardiac function and quality of life, while maintaining an acceptable safety profile.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"47437"},"PeriodicalIF":1.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors.","authors":"Jie Ma, Caie Li, Wenjuan Wang, Xin Fan, Taotao Wei, Xin Ma, Yingdong Wang, Chuyan Feng, Jing Yu","doi":"10.31083/RCM44942","DOIUrl":"https://doi.org/10.31083/RCM44942","url":null,"abstract":"<p><p>The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including deoxyribonucleic acid (DNA) repair, apoptosis, protein synthesis, cellular proliferation, and responses to oxidative stress. PARP inhibitors (PARPIs) exhibit selective cytotoxicity in cancers with breast cancer susceptibility gene (<i>BRCA</i>) mutations or defects in homologous recombination. Activation of PARP, indicated by increased poly(ADP-ribose) (PAR) accumulation, is implicated in various disease states such as ischemia-reperfusion injury, vascular disorders, and diabetic complications. Clinically, PARPIs, in combination with anti-angiogenic therapies, not only show efficacy as monotherapies in epithelial ovarian cancer but also mitigate hypertension induced by anti-angiogenic agents. This review consolidates recent advancements in understanding the dual therapeutic potential of PARP inhibition, encompassing both antineoplastic and cardioprotective effects.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"44942"},"PeriodicalIF":1.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements and Applications of Artificial Intelligence in Hypertrophic Cardiomyopathy: A Comprehensive Review.","authors":"Huanhuan Ma, Jing Li, Shengjun Ta, Liang Yu, Fangqi Ruan, Liwen Liu","doi":"10.31083/RCM44449","DOIUrl":"https://doi.org/10.31083/RCM44449","url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy (HCM) is a common cardiovascular disease and one of the leading causes of exercise-induced sudden cardiac death in adolescents. HCM presents complex diagnostic, prognostic, and management challenges due to the phenotypic heterogeneity and clinical course. Artificial intelligence (AI), machine learning (ML), and deep learning (DL) technologies are expected to transform the roles of echocardiography, electrocardiography (ECG), and cardiac magnetic resonance (CMR) imaging in the clinical management of HCM. AI methods can fully integrate clinical and imaging data to enable a comprehensive assessment of the risk profile of a patient. However, challenges remain, such as insufficient data standardization across multiple sources, limited model interpretability, and data privacy issues. Despite these challenges, AI-based approaches have the potential to revolutionize the management of HCM by providing timely, accurate diagnoses and personalized treatment strategies based on individual patient risk profiles. This review systematically examines the current landscape of AI applications in HCM data analytics, with a focus on methodological advancements and clinical implementations. Furthermore, this review aims to facilitate the transition from experience-based to data-driven paradigms in HCM diagnosis, thereby advancing precision medicine and individualized patient management.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"44449"},"PeriodicalIF":1.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Participation and Adherence in Cardiac Rehabilitation Programmes: A Scoping Review of Recent Evidence from Industrialized and Developing Countries.","authors":"Aliff Latir, Eliza Hafiz, Anwar Suhaimi","doi":"10.31083/RCM45898","DOIUrl":"https://doi.org/10.31083/RCM45898","url":null,"abstract":"<p><p>Participation and adherence to cardiac rehabilitation (CR) remain low worldwide; meanwhile, differences in barriers between industrialized and developing countries have not been well synthesized. A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines to map recent evidence (2014-2025) on barriers to CR participation and adherence in industrialized and developing settings. Searches conducted in major databases identified 538 records, of which 19 met the inclusion criteria for thematic analysis. Participation in CR ranged from 12.3% to 81% in industrialized countries and from 5% to 70% in developing settings, while adherence ranged from 70.8% to 90.3% and from 20.4% to 71.3%, respectively. Reported barriers can be clustered into patient-level beliefs and perceptions, logistical and work-related constraints, comorbidities and health status, socioeconomic and demographic factors, psychological characteristics, and health-system and environmental limitations. A wide variation in CR utilization persists globally, with distinct patterns of barriers across industrialized and developing contexts. These findings highlight the need for setting-specific strategies to improve CR participation and adherence.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"45898"},"PeriodicalIF":1.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies.","authors":"Panagiotis Theofilis, Panayotis K Vlachakis, Paschalis Karakasis, Panagiotis Iliakis, Konstantinos Pamporis, Evangelos Oikonomou, Kyriakos Dimitriadis, Konstantinos Tsioufis, Dimitris Tousoulis","doi":"10.31083/RCM46547","DOIUrl":"https://doi.org/10.31083/RCM46547","url":null,"abstract":"<p><strong>Background: </strong>Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) have emerged as a promising class of medications, primarily recognized for inducing potent cholesterol-lowering effects. In addition to the established role of these inhibitors in reducing low-density lipoprotein cholesterol levels, recent studies suggest that PCSK9is may also modify coronary atherosclerotic plaques. Therefore, this meta-analysis aimed to comprehensively synthesize data from relevant clinical studies and trials investigating the effects of PCSK9is on coronary atherosclerotic plaque characteristics.</p><p><strong>Methods: </strong>We performed a literature search for studies assessing the evolution of coronary atherosclerotic plaques after treatment with a PCSK9i compared with a control group. We excluded reviews, editorials, case reports/case series, and studies that did not use PCSK9is or lacked a control group. The main outcomes of interest were changes in percent atheroma volume (PAV), total atheroma volume (TAV), minimal fibrous cap thickness (FCT), lipid arc, and the number of patients with improved PAVs at follow-up. Effect sizes are presented as a standardized mean difference (SMD) or risk ratio (RR) alongside the corresponding 95% confidence intervals (CIs) and were pooled based on a random-effects model. Publication bias was assessed by funnel plot inspection and Egger's regression test.</p><p><strong>Results: </strong>The literature search yielded 142 results. After applying the exclusion criteria, nine studies were selected for data extraction and inclusion in the meta-analysis. Concerning the intravascular ultrasound findings, PCSK9is significantly reduced the TAV (MD -7.09 mm³, 95% CI -11.36 to -2.81; <i>p</i> = 0.01) and induced non-significant reductions in the PAV (MD -1.91%, 95% CI -5.08 to 1.25; <i>p</i> = 0.17); meanwhile, a greater proportion of patients treated with PCSK9 inhibitors exhibited an improvement in the PAV (RR 1.30, 95% CI 1.19 to 1.42; <i>p</i> < 0.001). For optical coherence tomography parameters, patients treated with PCSK9 inhibitors showed an increase in minimal FCT (MD 36.25 μm, 95% CI 0.75 to 71.75; <i>p</i> = 0.047) and a non-significant decrease in lipid arc (MD -17.64°, 95% CI -49.73 to 14.44; <i>p</i> = 0.14).</p><p><strong>Conclusions: </strong>This meta-analysis suggests that PCSK9i therapy may be associated with modest favorable changes in selected intravascular imaging markers of coronary atherosclerotic plaque burden and stability.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"46547"},"PeriodicalIF":1.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome Comparisons of Direct Coverage Versus Fenestration for an Isolated Left Vertebral Artery in Zone 2 TEVAR: A Retrospective Study.","authors":"Zuo Pu, Kun Fang, Jingbo Lu, Ying Zhang, Jiawei Zhao, Bowen Fan, Yi Liu, Mingyao Luo, Chang Shu","doi":"10.31083/RCM44615","DOIUrl":"https://doi.org/10.31083/RCM44615","url":null,"abstract":"<p><strong>Background: </strong>Thoracic endovascular aortic repair (TEVAR) in Zone 2 frequently necessitates coverage of the isolated left vertebral artery (ILVA), a congenital vascular anomaly, to ensure adequate proximal sealing. However, the clinical requirement of ILVA revascularization remains uncertain. Thus, this study aimed to compare the outcomes between ILVA coverage and fenestration during Zone 2 TEVAR.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical records of patients with ILVA who underwent Zone 2 TEVAR between September 2010 and August 2023. Patients were divided into two groups: Coverage Group (n = 23) and Fenestration Group (n = 33). Baseline characteristics, surgical outcomes, and changes in left and right vertebral artery diameters pre- and postoperatively were compared. Continuous variables were compared using Student's <i>t</i>-test or Mann-Whitney U test, depending on the distribution. Categorical variables were analyzed using the chi-square test or Fisher's exact test.</p><p><strong>Results: </strong>The overall cohort had a mean age of 54.48 ± 10.31 years, with 89.29% of participants male and a mean body mass index (BMI) of 25.88 ± 3.5 kg/m². The Fenestration Group was significantly older than the Coverage Group (56.82 ± 8.78 vs. 51.13 ± 11.56; <i>p</i> = 0.04). Technical success of the TEVAR was achieved in both groups in 98.21% of cases, with no perioperative mortality. Simultaneous left subclavian artery stenting was performed more frequently in the Fenestration Group (57.58% vs. 21.74%; <i>p</i> = 0.008). At discharge, patients in the Coverage Group demonstrated a significantly greater reduction in left vertebral artery diameter compared with the Fenestration Group (13.64% [5.52%, 22.4%] vs. 0 [-3.29%, 5.13%]; <i>p</i> < 0.001). The incidence of vertebral artery diameter reduction was significantly higher in the Coverage Group compared with the Fenestration Group (39.13% vs. 6.06%; <i>p</i> < 0.01). Follow-up computed tomography angiography demonstrated a greater reduction in left vertebral artery diameter in the Coverage Group (52.94% vs. 14.29%; <i>p</i> = 0.020), while occlusion rates were comparable between groups (29.41% vs. 4.76%; <i>p</i> = 0.070).</p><p><strong>Conclusions: </strong>Fenestration is associated with a lower incidence of postoperative ILVA diameter reduction compared with direct coverage during Zone 2 TEVAR. These findings highlight the potential benefit of ILVA revascularization and underscore the need for further validation in larger studies.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"44615"},"PeriodicalIF":1.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Genetic Counseling in Cardiology Clinics: From Guidelines to Practice.","authors":"Despina Sanoudou, Styliani Vakrou, Alexandra Frogoudaki","doi":"10.31083/RCM48695","DOIUrl":"https://doi.org/10.31083/RCM48695","url":null,"abstract":"","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"27 3","pages":"48695"},"PeriodicalIF":1.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13036541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}